Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Vaccines comprising innovative adjuvants are rapidly reaching advanced translational
stages, such as the authorized nanotechnology adjuvants in mRNA vaccines against COVID …

Background Malaria control remains a challenge in many parts of the Sahel and sub-Sahel
regions of Africa. Methods We conducted an individually randomized, controlled trial to …

Background CIS43LS is a monoclonal antibody that was shown to protect against controlled
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Natural infections expose the immune system to escalating antigen and inflammation over
days to weeks, whereas nonlive vaccines are single bolus events. We explored whether the …

Summary Background Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically
active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe …

The need to optimize vaccine potency while minimizing toxicity in healthy recipients has
motivated studies of the formulation of vaccines to control how, when, and where antigens …

Adjuvants incorporated in prophylactic and/or therapeutic vaccine formulations impact
vaccine efficacy by enhancing, modulating, and/or prolonging the immune response. In …

Summary Background The RTS, S/AS01 malaria vaccine targets the circumsporozoite
protein, inducing antibodies associated with the prevention of Plasmodium falciparum …